TY - JOUR
T1 - Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge
T2 - Effect of systemic corticosteroids and relationship to eosinophil influx
AU - Bascom, Rebecca
AU - Pipkorn, Ulf
AU - Proud, David
AU - Dunnette, Sandra
AU - Gleich, Gerald J.
AU - Lichtenstein, Lawrence M.
AU - Naclerio, Robert M.
N1 - Funding Information:
From the Department of Medicine, Division of Clinical Immunol-ogy, and Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Md.; and the Departments of Immunology and Medicine, Mayo Medical School, Mayo Clinic and Foundation, Rochester, Minn. Supported in part by National Institutes of Health Grants AI 20136, AI 04866, AI 08270, AI 15231, AI 11483, NS 22488, and HL 32272. Received for publication June 30, 1988. Revised March 20, 1989. Accepted for publication March 20, 1989. Reprint requests: Robert M. Naclerio, MD, Professional Office Building, Suite 402, 5601 Loch Raven Blvd., Baltimore, MD 21239.
Funding Information:
*Supported in part by the American Lung Association of Maryland. Present address: Pulmonary Division, The University of Mary-land School of Medicine. Baltimore, MD 21201. **Recipient of International Research Fellowship Award from the Fogarty International Center, NIH FO 5 TWO 3516-01. Present address: Department of Otolaryngology, University Hospital, Lund, Sweden. ***Recipient of a Pfizer Biomedical Research award. ****Recipient of the National Institute of Neurological and Com-municative Disorders and Stroke Teacher Investigator Devel-opment Award NS 008 11. Publication No. 758 from the O’Neill Laboratories, The Good Samaritan Hospital, Baltimore, Md. 1/1/13009
PY - 1989/9
Y1 - 1989/9
N2 - The late-phase response to nasal challenge with antigen is associated with a mixed inflammatory cell influx in which the eosinophil demonstrates the earliest and greatest proportionate rise. We investigated the evidence for activation of the eosinophil during the late response by measuring the concentration of the eosinophil-derived mediator major basic protein (MBP) and the eosinophil-derived neurotoxin (EDN) in nasal-lavage fluids before and for 11 hours after antigen challenge in 13 subjects with seasonal allergic rhinitis. The subjects received oral prednisone (20 mg three times daily) or placebo in a double-blind, crossover manner for 2 days before each of two antigen challenges. After placebo pretreatment, significant increases over diluent baseline (4.5 ± 0.4 ng/ml) occurred in the levels of MBP in nasal-lavage fluid during the early (9.8 ± 2.9 ng/ml; p < 0.005) and late (15.3 ± 4.8 ng/ml; p < 0.01) responses to antigen challenge. Significant increases (p < 0.05) in the concentration of EDN also occurred during the late response to antigen that correlated with the levels of MBP (r = 0.48; p < 0.001). The cumulative late-phase increase in MBP correlated closely (rs = 0.96; p < 0.005) with the total influx of eosinophils. Oral prednisone pretreatment significantly reduced the mean of each subject's peak late-phase concentration of both MBP (30.7 ± 5.8 ng/ml versus 13.3 ± 4.3 ng/ml; p = 0.005) and EDN (885 ± 659 ng/ml versus 71 ± 41 ng/ml; p < 0.05). These data provide evidence for eosinophil degranulation during the late response and inhibition of this response by prednisone, supporting its pathogenetic role.
AB - The late-phase response to nasal challenge with antigen is associated with a mixed inflammatory cell influx in which the eosinophil demonstrates the earliest and greatest proportionate rise. We investigated the evidence for activation of the eosinophil during the late response by measuring the concentration of the eosinophil-derived mediator major basic protein (MBP) and the eosinophil-derived neurotoxin (EDN) in nasal-lavage fluids before and for 11 hours after antigen challenge in 13 subjects with seasonal allergic rhinitis. The subjects received oral prednisone (20 mg three times daily) or placebo in a double-blind, crossover manner for 2 days before each of two antigen challenges. After placebo pretreatment, significant increases over diluent baseline (4.5 ± 0.4 ng/ml) occurred in the levels of MBP in nasal-lavage fluid during the early (9.8 ± 2.9 ng/ml; p < 0.005) and late (15.3 ± 4.8 ng/ml; p < 0.01) responses to antigen challenge. Significant increases (p < 0.05) in the concentration of EDN also occurred during the late response to antigen that correlated with the levels of MBP (r = 0.48; p < 0.001). The cumulative late-phase increase in MBP correlated closely (rs = 0.96; p < 0.005) with the total influx of eosinophils. Oral prednisone pretreatment significantly reduced the mean of each subject's peak late-phase concentration of both MBP (30.7 ± 5.8 ng/ml versus 13.3 ± 4.3 ng/ml; p = 0.005) and EDN (885 ± 659 ng/ml versus 71 ± 41 ng/ml; p < 0.05). These data provide evidence for eosinophil degranulation during the late response and inhibition of this response by prednisone, supporting its pathogenetic role.
UR - http://www.scopus.com/inward/record.url?scp=0024436975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024436975&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(89)90418-1
DO - 10.1016/0091-6749(89)90418-1
M3 - Article
C2 - 2778240
AN - SCOPUS:0024436975
SN - 0091-6749
VL - 84
SP - 338
EP - 346
JO - The Journal of Allergy and Clinical Immunology
JF - The Journal of Allergy and Clinical Immunology
IS - 3
ER -